Perry's The Chemotherapy Source BookMichael Clinton Perry, Donald C. Doll, Carl E. Freter Lippincott Williams & Wilkins, 2012 - 833 The Chemotherapy Sourcebook, first published in '92, was one of the original anchors of the W&W oncology list. It was the first comprehensive book to pull together all current information on the chemotherapeutic management of cancer patients, providing information the choice of chemotherapeutic agents, the use of combinations, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy. |
Spis treści
Principles of Chemotherapy | 38 |
Routes of Administration | 80 |
Management of Drug Toxicity | 112 |
Cardiotoxicity of Cancer Therapy | 194 |
21 | 252 |
Vascular Toxicity of Antineoplastic Agents | 272 |
Gonadal Complications and Teratogenicity | 321 |
Drug Administration | 337 |
Gastrointestinal Cancer | 445 |
Endocrine Tumors | 457 |
Chemotherapy of Genitourinary Cancer | 466 |
Chemotherapy ofGynecologic Cancers | 500 |
Chemotherapy ofCarcinoma of Unknown Primary Site | 512 |
Chemotherapy ofBone and Soft Tissue Sarcomas | 526 |
Chemotherapy for Pediatric Solid Tumors | 546 |
Chemotherapy of Hematologic | 552 |
Current Therapy of Specific Solid Tumors | 345 |
Chemotherapy ofPrimary Brain Tumors | 355 |
Breast Cancer | 401 |
Myelodysplastic Syndromes 619 Christopher R Cogle Rami S Komrokji and Alan F List III Common Terminology Criteria for Adverse | 791 |
Inne wydania - Wyświetl wszystko
Perry's The Chemotherapy Source Book Michael C. Perry,Donald C. Doll,Carl E. Freter Ograniczony podgląd - 2012 |
Kluczowe wyrazy i wyrażenia
activity acute addition adjuvant administration agents appears associated benefit Blood bone marrow breast cancer cancer patients carcinoma catheter cause cell changes chemotherapeutic chemotherapy chronic cisplatin Clin Oncol clinical clinical trials combination compared complete complications concurrent continuous cycles cyclophosphamide demonstrated disease docetaxel dose doxorubicin drug effects et al evaluation factor function given Group growth head and neck hepatic high-dose HSRs human Ifosfamide imatinib improved incidence increased induced infection infusion initial interferon involved leukemia levels liver lung cancer lymphoma malignant melanoma metastatic methotrexate months mucositis myocardial infarction normal observed occur Oncology oral paclitaxel patients phase potential pregnancy prevention progression radiation randomized reactions receiving recurrent reduced regimens renal reported resistance response response rate risk severe significant stage syndrome systemic Table therapy tion toxicity transplantation treated treatment tumor versus vincristine weeks women